Skip to main content
Clinical Trials/NCT05451121
NCT05451121
Completed
Not Applicable

Comparing Effect of Propofol, Dexmedetomidine and Their Combination on Duration Mechanical Ventilation in Patient After Cardiac Surgery

Anesthesia Research Group UA1 site in 1 country356 target enrollmentJuly 1, 2017

Overview

Phase
Not Applicable
Intervention
Propofol
Conditions
Respiratory Failure
Sponsor
Anesthesia Research Group UA
Enrollment
356
Locations
1
Primary Endpoint
length of the mechanical ventilation
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

There is a direct relationship between the sedative agent and the duration of ventilation.

Detailed Description

Sedation and sedative agent have direct correlation to the mechanical length. As known mechanical length could increase length of the hospital stay (LOHS) and mortality rate. The right sedative agent can decrease the length go the mechanical ventilation. The goal of the research to compare 3 sedation strategies and their influence to the duration of mechanical ventilation.

Registry
clinicaltrials.gov
Start Date
July 1, 2017
End Date
July 1, 2019
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Anesthesia Research Group UA
Responsible Party
Principal Investigator
Principal Investigator

Plechysta Yelyzaveta

Chief of the anesthesia department

Anesthesia Research Group UA

Eligibility Criteria

Inclusion Criteria

  • Multi vascular lesions of the coronary arteries according to coronary angiography;
  • Heart valve damage was confirmed by, which is subject to surgical correction (aortic stenosis of III degree with a gradient on the aortic valve of more than 42 mmHg, aortic insufficiency III, mitral valve stenosis II-III, mitral regurgitation II-III)
  • Age of patients from 18-80 years; • Patient consent to participate in the study;

Exclusion Criteria

  • Refusal to participate;
  • Hypersensitivity to propofol, dexmedetomidine;
  • Prolonged mechanical ventilation in case of surgical complications (bleeding, inadequate perfusion of the myocardium);
  • Occurred ischemic stroke;
  • History of the ischemic stroke;
  • History of the neurodegenerative diseases;
  • History of the mental disorders;
  • Use of neuroleptics, antidepressants for the last 5 years;
  • History of the cardiac surgery in the past;
  • Patients with chronic pulmonary disease (GOLD 3-4)

Arms & Interventions

propofol

Patient sedation after cardiac surgery at the intensive care unit. Continuous infusion of propofol (hypnotic agent) using a syringe pump at the dose of 1-1.5 mg / kg / h

Intervention: Propofol

Dexmedetomidine

Patient sedation after cardiac surgery at the intensive care unit. continuous infusion of Dexmedetomidine (selective α2-adrenergic receptor (α2-AR) agonist) using a syringe pump at the dose of 0.5-1.0 mcg/ kg / h

Intervention: Dexmedetomidine

propofol and dexmedetomidine

Patient sedation after cardiac surgery at the intensive care unit. Continuous infusion of propofol using a syringe pump at the dose of 0.5-1.5 mg / kg / h and dexmedetomidine 0.2-0.7 mcg\\kg\\h

Intervention: Propofol and dexmedetomidine

Outcomes

Primary Outcomes

length of the mechanical ventilation

Time Frame: after cardiac surgery till extubation (up to first 24 hour after surgery)

measure the length of the mechanical ventilation

Secondary Outcomes

  • Length of the ICU stay(at the day of discharge of ICU (assessed up to day 5))
  • Length of the hospital stay(at the day of discharge of hospital (assessed up to day 5))

Study Sites (1)

Loading locations...

Similar Trials